Patents Examined by Nizal S. Chandrakumar
  • Patent number: 10323017
    Abstract: A method of preventing or reducing the level of degradation of an organic substrate is described, wherein a composition is formed that includes the organic substrate together with an effective amount of a sacrificial base and a diarylamine antioxidant.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 18, 2019
    Assignees: Alma Mater Studiorum—Universita di Bologna, University of Ottawa
    Inventors: Derek A. Pratt, Ronak Mayankbhai Shah, Evan Anthony Haidasz, Luca Valgimigli
  • Patent number: 10322136
    Abstract: Provided are a composition for inhibiting growth or proliferation of chronic myelogenous leukemia (CML) cancer stem cells, a pharmaceutical composition for preventing or treating CML, a method for preventing or treating CML, and a method of screening for a growth or proliferation inhibitor of CML cancer stem cells by blocking nutrient signaling in CML cancer stem cells.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: June 18, 2019
    Assignee: HIROSHIMA UNIVERSITY
    Inventors: Seong Jin Kim, Kazuhito Naka
  • Patent number: 10316034
    Abstract: The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: June 11, 2019
    Assignee: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Edward Savory, Michael Higginbottom
  • Patent number: 10319523
    Abstract: A composite polymeric material includes one or more repeating backbone units; one or more polarizable units incorporated into or connected to one or more of the one or more repeating backbone units; and one or more resistive tails connected to one or more of the repeating backbone units or to the one or more polarizable units as a side chain on the polarizable unit, on a hydrocarbon chain linking a polarizable unit to a backbone unit, or directly attached to a backbone unit. The composite polymeric material may be used to form a metadielectric, which may be sandwiched between to electrodes to form a metacapacitor.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: June 11, 2019
    Assignee: CAPACITOR SCIENCES INCORPORATED
    Inventors: Yan Li, Pavel Ivan Lazarev, Paul T. Furuta, Barry K. Sharp, Samuel Hein
  • Patent number: 10292978
    Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 21, 2019
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva
  • Patent number: 10292989
    Abstract: The present application discloses the unexpected result that a neuroactive steroid such as B260 can act as a general anesthetic and that it has no neurotoxic side effects such as impairing brain development.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 21, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Vesna Jevtovic-Todorovic, Slobodan Todorovic
  • Patent number: 10292970
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 21, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • Patent number: 10287220
    Abstract: The present invention relates to a process for producing an organic compound comprising an 18F atom. The compounds comprising an 18F can be useful as PET ligands for use in diagnostics and/or scanning. The process of the invention comprises treating an organoboron compound, which organoboron compound comprises a boron atom bonded to an sp2 hybridized carbon atom, with (i) 18F— and (ii) a copper compound. The invention also provides the use of an organoboron compound, which organoboron compound comprises a boron atom bonded to an sp2 hybridized carbon atom, in a process for producing an organic compound comprising an 18F atom, which process comprises treating the organoboron compound with (i)18F— and (ii) a copper compound.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: May 14, 2019
    Assignee: Oxford University Innovation Limited
    Inventors: Veronique Gouverneur, Matthew Tredwell, Sean Preshlock
  • Patent number: 10278386
    Abstract: The present invention relates to a solution for resisting destruction of living plants and a related method. A solution including a buffered amine oxide admixed with at least one material selected from the group consisting of insecticides and fungicides is applied to the living plant and provides a synergistically effective greater resistance to living plant deterioration than any of the individual buffered amine oxide, insecticides and fungicide achieve considered individually. A related method is disclosed.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: May 7, 2019
    Assignee: KOP-COAT, INC.
    Inventors: Hans A. Ward, Ronald Walton Clawson, Jr., Kenneth Allen Cutler, Cameron R. Scott
  • Patent number: 10273241
    Abstract: Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof. Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the -catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGF?/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: April 30, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Matthew D. Shair, Juergen Ramharter, Henry Efrem Pelish, Brian Bor-Jen Liau, Jae Young Ahn
  • Patent number: 10266492
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: April 23, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Patent number: 10265305
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 23, 2019
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Patent number: 10258980
    Abstract: The present invention relates to metal complexes and methods of synthesizing the metal complexes. The invention is further directed to pharmaceutical and/or dietary supplement composition comprising compounds synthesized as described herein.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 16, 2019
    Assignee: C Lab Pharma International, S.A.
    Inventors: Charles Louis Albartus Barker, Siead Zegar, Kurt Wachholder
  • Patent number: 10259812
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: April 16, 2019
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • Patent number: 10259784
    Abstract: The present invention relates to methods of synthesizing aziridines including isotopically labelled aziridines, said methods comprising contacting an imine or one or more precursors thereof with a diazo compound in the presence of a phosphoramide or a phosphoramide-derived catalyst. The present invention also relates to aziridines, modified aziridines and aziridine-derived compounds preparable by the aforementioned methods, and to phosphoramide or phosphoramide-derived catalysts suitable for use in such methods.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: April 16, 2019
    Assignee: University of East Anglia
    Inventors: Sean Patrick Bew, Sean Michael Thurston, Paolo Pesce
  • Patent number: 10251890
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: April 9, 2019
    Assignee: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 10251872
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 9, 2019
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, Son Minh Pham, David Charles Williams, David Ben Kita
  • Patent number: 10246444
    Abstract: Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: April 2, 2019
    Assignee: SABILA BIOSCIENCES LLC
    Inventor: Tarek Suhayl Mansour
  • Patent number: 10246410
    Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 2, 2019
    Assignee: Life Technologies Corporation
    Inventors: Wenjun Zhou, Kyle Gee, Yolanda Tennico, Peter Slade, Hee Chol Kang, Shaheer Khan, Brian Evans, James Stray
  • Patent number: 10246553
    Abstract: In an organic fluorine compound, an organic group including a single aromatic ring or a condensed ring consisting of aromatic rings at a non-bonded terminal is bonded to each of all of terminals of a chain structure including a perfluoropolyether structure.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 2, 2019
    Assignee: SHOWA DENKO K.K.
    Inventors: Kentaro Watanabe, Yasuyuki Ueda, Takeshi Igarashi